85 related articles for article (PubMed ID: 23155322)
1. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response.
Samiullah S; Bikharam D; Nasreen
World J Gastroenterol; 2012 Oct; 18(40):5793-8. PubMed ID: 23155322
[TBL] [Abstract][Full Text] [Related]
2. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.
Guedj J; Rotman Y; Cotler SJ; Koh C; Schmid P; Albrecht J; Haynes-Williams V; Liang TJ; Hoofnagle JH; Heller T; Dahari H
Hepatology; 2014 Dec; 60(6):1902-10. PubMed ID: 25098971
[TBL] [Abstract][Full Text] [Related]
3. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
[TBL] [Abstract][Full Text] [Related]
4. Therapy of Delta Hepatitis.
Yurdaydin C; Idilman R
Cold Spring Harb Perspect Med; 2015 Aug; 5(10):. PubMed ID: 26253093
[TBL] [Abstract][Full Text] [Related]
5. Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.
Anastasiou OE; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Heidrich B; Mederacke I; von der Leyen H; Kahlhöfer J; von Karpowitz M; Hardtke S; Cornberg M; Yurdaydin C; Wedemeyer H
Liver Int; 2024 Jan; 44(1):139-147. PubMed ID: 37787009
[TBL] [Abstract][Full Text] [Related]
6. Interferon-based treatment of chronic hepatitis D.
Sandmann L; Wedemeyer H
Liver Int; 2023 Aug; 43 Suppl 1():69-79. PubMed ID: 36002390
[TBL] [Abstract][Full Text] [Related]
7. Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Dinkelborg K; Kahlhöfer J; Dörge P; Yurdaydin C; Hardtke S; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Weber K; Stift J; Wittkop U; Heidrich B; Mederacke I; von der Leyen H; Dienes HP; Cornberg M; Koch A; Manns MP; Wedemeyer H; Deterding K;
Liver Int; 2023 Aug; 43(8):1663-1676. PubMed ID: 37183524
[TBL] [Abstract][Full Text] [Related]
8. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Wedemeyer H; Aleman S; Brunetto MR; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Manuilov D; Suri V; An Q; Da B; Flaherty J; Osinusi A; Liu Y; Merle U; Schulze Zur Wiesch J; Zeuzem S; Ciesek S; Cornberg M; Lampertico P;
N Engl J Med; 2023 Jul; 389(1):22-32. PubMed ID: 37345876
[TBL] [Abstract][Full Text] [Related]
9. Correlation between TH1 response standard cytokines as biomarkers in patients with the delta virus in the western Brazilian Amazon.
Nicolete LD; Borzacov LM; Vieira DS; Nicolete R; Salcedo JM
Mem Inst Oswaldo Cruz; 2016 Apr; 111(4):275-6. PubMed ID: 27074258
[TBL] [Abstract][Full Text] [Related]
10. Management of autoimmune hepatitis induced by hepatitis delta virus.
Gigi E; Lagopoulos V; Liakos A
World J Gastroenterol; 2024 Feb; 30(8):799-805. PubMed ID: 38516234
[TBL] [Abstract][Full Text] [Related]
11. Bulevirtide for patients with compensated chronic hepatitis delta: A review.
Degasperi E; Anolli MP; Lampertico P
Liver Int; 2023 Aug; 43 Suppl 1():80-86. PubMed ID: 35942695
[TBL] [Abstract][Full Text] [Related]
12. Interferon alpha-2b therapy in chronic hepatitis delta.
Keshvari M; Alavian SM; Sharafi H; Karimi G; Gholami Fesharaki M
Hepat Mon; 2014 Mar; 14(3):e15729. PubMed ID: 24744790
[TBL] [Abstract][Full Text] [Related]
13. Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D.
Gherlan GS; Lazar SD; Culinescu A; Smadu D; Vatafu AR; Popescu CP; Florescu SA; Ceausu E; Calistru PI
Trop Med Infect Dis; 2024 Mar; 9(4):. PubMed ID: 38668534
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.
Yurdaydin C; Keskin O; Yurdcu E; Çalişkan A; Önem S; Karakaya F; Kalkan Ç; Karatayli E; Karatayli S; Choong I; Apelian D; Koh C; Heller T; Idilman R; Bozdayi AM; Glenn JS
Hepatology; 2022 Jun; 75(6):1551-1565. PubMed ID: 34860418
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B Delta: assessment of the knowledge and practices of hepato-gastroenterologists practicing in non-academic settings in France.
Cadranel JD; Zougmoré HT; Efole JN; Hanslik B; Causse X; Rosa I; Lemaitre C; Mokhtari C; Baron A; Thevenot T; Medmoun M; Smadhi R; Fantognon G; Remy AJ; Macaigne G; Arondel Y; Arpurt JP; Bellaiche G; Bourlière M; De Kerguenec C; Heluwaert F; Verlynde J; Halfon P; Roulot D; Carrier P; Loustaud-Ratti V; Lemagoarou T;
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):735-741. PubMed ID: 38683191
[TBL] [Abstract][Full Text] [Related]
16. Increase in HDV replication during steroid therapy - potential implications for testing and treatment strategies.
Patmore LA; van der Eijk AA; Janssen HLA; de Man RA; Sonneveld MJ
J Hepatol; 2024 Jul; 81(1):e49-e50. PubMed ID: 38036005
[No Abstract] [Full Text] [Related]
17. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial.
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Ciesek S; Manuilov D; Mercier RC; Da BL; Chee GM; Li M; Flaherty JF; Lau AH; Osinusi A; Schulze Zur Wiesch J; Cornberg M; Zeuzem S; Lampertico P
J Hepatol; 2024 May; ():. PubMed ID: 38734383
[TBL] [Abstract][Full Text] [Related]
18. Reply: To PMID 25098971.
Guedj J; Canini L; Cotler S; Dahari H
Hepatology; 2015 Jun; 61(6):2118-9. PubMed ID: 25363327
[No Abstract] [Full Text] [Related]
19. Autoimmune Hepatitis Induced by Hepatitis Delta Virus: A Conundrum.
Cardoso MF; Carvalho R; Correia FP; Branco JC; Costa MN; Martins A
GE Port J Gastroenterol; 2024 Jun; 31(3):203-208. PubMed ID: 38836124
[TBL] [Abstract][Full Text] [Related]
20. Letter to the Editor: HDV therapy-evolving success parameters.
Tiwari A; Khanikar D; Bharali P; Prajapati SK; Gattani R
Hepatology; 2023 Jun; 77(6):E178-E179. PubMed ID: 36976543
[No Abstract] [Full Text] [Related]
[Next] [New Search]
